J. Cooper

Survival after pancreatectomy for pancreatic adenocarcinoma is not impacted by performance status.

John E. Mullinax, A. Rosemurgy, Jonathan M. Hernandez, 2012, American journal of surgery.

CA 19-9 Velocity Predicts Disease-Free Survival and Overall Survival After Pancreatectomy of Curative Intent

A. Rosemurgy, S. Ross, E. Zervos, 2009, Journal of Gastrointestinal Surgery.

An Aggressive Approach to Extrahepatic Cholangiocarcinomas Is Warranted: Margin Status Does Not Impact Survival after Resection

John E. Mullinax, A. Rosemurgy, S. Ross, 2008, Annals of Surgical Oncology.

32P as an Adjunct to Standard Therapy for Locally Advanced Unresectable Pancreatic Cancer: A Randomized Trial

M. Bloomston, A. Rosemurgy, L. Carey, 2008, Journal of Gastrointestinal Surgery.

Phase I and pharmacokinetics (PK) study of sequential paclitaxel and trabectedin every 2 weeks in patients with advanced solid tumors.

A. Tolcher, K. Papadopoulos, A. Patnaik, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: phase III randomized Intergroup study 0099.

M. Leblanc, J. Cooper, K. Fu, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Natural History of Resected Pancreatic Cancer without Adjuvant Chemotherapy

A. Rosemurgy, S. Al-Saadi, Jonathan M. Hernandez, 2010, The American surgeon.

TNFα gene delivery therapy for solid tumors

A. Rosemurgy, Jonathan M. Hernandez, J. Cooper, 2010, Expert opinion on biological therapy.

A phase II trial of paclitaxel and cisplatin in patients with locally advanced metastatic esophageal cancer: a preliminary report.

M. Bains, R. Ginsberg, D. Kelsen, 1997, Seminars in oncology.